I. Administrative Information
Risk: Severe hypocalcemia
Application Number: BLA 761436
Application Holder: Biocon Biologics Inc
Initial REMS Approval: 09/2025
Most Recent REMS Update: 12/2025
Risk: Severe hypocalcemia
Application Number: BLA 761436
Application Holder: Biocon Biologics Inc
Initial REMS Approval: 09/2025
Most Recent REMS Update: 12/2025
The goal of the BOSAYA REMS is to mitigate the risks of severe hypocalcemia in patients with advanced chronic kidney disease (CKD), including dialysis-dependent patients, associated with BOSAYA.
Objective 1: Inform healthcare providers on:
- Risk of severe hypocalcemia in patients with advanced chronic kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2)
- Need to assess for the presence of chronic kidney disease-mineral bone disorder (CKD-MBD) before initiating BOSAYA in patients with advanced chronic kidney disease.
To inform healthcare providers about the REMS and the risk and safe use of BOSAYA, Biocon Biologics Inc. must disseminate REMS communication materials according to the table below:
| Target Audience | Communication Materials & Dissemination Plans |
|---|---|
| Healthcare providers who are likely to prescribe BOSAYA | REMS Letters: REMS Letter for Healthcare Providers, REMS Letter for Professional Societies with attachment, Prescribing Information.
Patient Guide and Prescribing Information 1.Disseminate and prominently display at Professional Meetings where Biocon Biologics Inc. has a BOSAYA commercial presence from the date BOSAYA is first commercially distributed for the duration of the REMS. 2.Disseminate through field-based sales and medical representatives during the initial and/or follow-up discussion with healthcare providers from the date BOSAYA is first commercially distributed for the duration Website 1. Make the REMS Website fully operational and all REMS materials available through the website by the date BOSAYA is first commercially distributed. |
Biocon Biologics Inc. must submit REMS Assessments at 18 months, 3 years, and 7 years from the date of the initial approval of the REMS (09/16/2025). To facilitate the inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. Biocon Biologics Inc. must submit each assessment so that it will be received by the FDA on or before the due date.
The following materials are part of the BOSAYA REMS:
Training and Educational Material
Patient:
Communication Materials
Other Material
This REMS is required under section 505-1 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355-1) and consists of the following elements:
| DailyMed label | Relation | Version | Effective | Manufacturer | Source |
|---|---|---|---|---|---|
| These highlights do not include all the information needed to use BOSAYA safely and effectively. See full prescribing information for BOSAYA. BOSAYA TM (denosumab-kyqq) injection, for subcutaneous use Initial U.S. Approval: 2025 BOSAYA TM (denosumab-kyqq) is biosimilar* to PROLIA ® (denosumab). | SPL related document | 2026-03-27 | Biocon Biologics Inc. | Biocon Biologics Limited | 20260113_f815637a-d201-4b22-bcb3-a278a611d6a4.zip!de7a0dc3-9cdc-4b0a-a7c1-43db1a97242b.xml |
Every source-derived product name is available through these pages.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BOSAYA | DENOSUMAB-KYQQ | Biocon Biologics Inc. | 1e5e8c88-3c65-3076-e44b-02d92c2d343d | 2026-03-27 | Boxed warning, Warnings, Adverse reactions | BOSAYA |
Adverse event summaries are temporarily unavailable. Other product information remains available.